ASH Conference Coverage

Advances in Multiple Myeloma, Lymphoma, and Histiocytosis among Results Presented at 2017 ASH Meeting

(MSK/OnCancer Blog) Dec 12, 2017 - At the 2017 meeting, held December 9 to 12 in Atlanta, Memorial Sloan Kettering researchers reported important progress in the treatment of several blood cancers.

read article

ASH 2017 – Transcend Fails To Prevent Juno’s Second Collapse

(EP Vantage) Dec 12, 2017 - Juno had hoped that the Ash meeting would mark its return as a competitive force in CAR-T. Instead, a keenly awaited update of its now pivotal lymphoma trial, Transcend, disappointed, and yesterday’s 14% share price collapse marked the second year in a row that Ash left the company nursing heavy losses.

read article

BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia

(Morningstar) Dec 14, 2017 - BioSight Ltd, a pharmaceutical development company, focused on the development of targeted oncology drugs, reports positive final results in a Phase I/II multi-center, open label, dose-escalating study of its lead product BST-236, a novel cytarabine pro-drug, as a single agent for induction therapy in acute leukemia patients.

read article

Study Shows Survival Benefits For Seeing An NCI Specialist For Multiple Myeloma

(UNC Lineberger) Dec 12, 2017 - Patients with multiple myeloma who saw a specialist at a National Cancer Institute-designated comprehensive Cancer Center had better overall survival than patients who only saw a community oncologist, according to a study from the University of North Carolina Lineberger Comprehensive Cancer Center.

read article

Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

(Markets Insider) Dec 12, 2017 - Servier, Pfizer Inc. and Cellectis presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta preliminary results from two phase 1 studies of UCART19, an investigational allogeneic anti-CD19 CAR T-cell product, in adult and pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population.

read article

Interdisciplinary Teams Can Help Decrease Hospital Readmissions

(CureToday.com) Dec 13, 2017 - Hospital readmissions soon after discharge can be costly and detrimental to patient care, but according to a recent study conducted at the Cleveland Clinic and presented at the 2017 American Society of Hematology’s Annual Meeting and Exposition, creating an interdisciplinary team to work with patients can help.

read article

Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

(Markets Insider) Dec 12, 2017 - Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today highlighted presentations and data from the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia, December 9-12, 2017.

read article

Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)

(Yahoo! Finance) Dec 13, 2017 - Spectrum Pharmaceuticals announced two oral presentations of data on FOLOTYN and research progress for the treatment of Peripheral T-Cell Lymphoma (PTCL) at the 59th American Society of Hematology (ASH).

read article

Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented

(NASDAQ) Dec 13, 2017 - Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, presented detailed data from its SL-401 pivotal trial in BPDCN, as well as results from other ongoing trials in additional indications, at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held in Atlanta, GA.

read article

Celgene CEO: New Therapies For A Certain Type Of Cancer Boost Survival Rates 10-Fold

(CNBC) Dec 11, 2017 - A new approach to treating patients suffering from an aggressive form of blood cancer could increase survival rates 10-fold to 20 years, Celgene CEO Mark Alles told CNBC on Monday.

read article

Chemotherapy-Free Cancer Treatments Move Closer To Reality

(Forbes) Dec 12, 2017 - CAR T-cell treatments continue to achieve impressive results in treating an ever-increasing variety of cancers, but will they ever be able to completely replace chemotherapy?

read article

ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More

(Xconomy National) Dec 11, 2017 - The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus the more notable market movements.

read article

Immuno-Oncology Drug Development -- Too Much Of A Good Thing?

(Forbes) Dec 12, 2017 - The annual meeting of the American Society of Hematology (ASH), now wrapping up in Atlanta, has generated a lot of excitement about immuno-oncology treatments like Bluebird Bio and Celgene’s experimental CAR-T targeting multiple myeloma.

read article

GSK Hails Progress On Its Most Advanced Cancer Drug

(The Telegraph [UK]) Dec 12, 2017 - Britain's biggest drugmaker GSK has hailed progress on its most advanced cancer drug, as the FTSE 100 firm battles to claw back lost ground in one of the world's most competitive medicines markets.

read article

Life-Shortening Blood Disease Gets Rush of Gene-Based Research

(Bloomberg) Dec 12, 2017 - More than 50 years after the cause of sickle-cell disease was discovered, a dozen treatments for the painful and life-shortening inherited condition offer hope for long-overlooked patients.

read article

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

(Kyowa Kirin) Dec 11, 2017 - Kyowa Hakko Kirin Co., Ltd. announced today that the results of the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab (KW-0761) in patients with cutaneous T-cell lymphoma (CTCL) will be presented at the Annual Meeting of American Society of Hematology 2017.

read corporate press release

GSK Presents Promising New Data For Priority BCMA Asset From Its Emerging Oncology Pipeline At 59th ASH Meeting

(GSK) Dec 11, 2017 - GlaxoSmithKline plc today presented promising new data from the dose expansion phase of the DREAMM-1 study of GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate.

read corporate press release

Miragen Therapeutics Presents New Interim Clinical Data Expanding On Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 On Mycosis Fungoides Form Of Cutaneous T-cell Lymphoma At 2017 American Society Of Hematology Annual Meeting

(Miragen) Dec 11, 2017 - miRagen Therapeutics, Inc. announced today new interim results from its ongoing Phase 1 clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).

read corporate press release

Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study

(Adaptimmune) Dec 11, 2017 - Adaptimmune Therapeutics plc submitted updated data from its completed pilot study1 of NY-ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented by the main investigator at the annual ASH meeting.

read corporate press release

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

(Yahoo! Finance) Dec 11, 2017 - Final results from the company’s phase I/II study of NiCord® demonstrate important potential as a universal transplantation solution for patients with high-risk blood cancers; preclinical study of NAM-NK Cells supports utility as an immunotherapeutic modality for treating cancer.

read article
Next Page